A cluster-randomized trial of 33,995 adults with uncontrolled hypertension across 326 villages in rural China found that an intensive, village-health-worker-delivered blood pressure program cut all-cause dementia by 15 percent over four years. The intervention drove systolic pressure down 22 mmHg further than usual care, from roughly 157 to 128 mmHg, and produced 668 dementia cases versus 734 in controls. Cognitive impairment short of dementia fell by a similar 15 to 16 percent, and serious adverse events were slightly lower in the treated arm rather than higher. This is the first adequately powered randomized trial to show a statistically significant dementia reduction from blood pressure lowering, converting decades of observational association into causal evidence.
For thirty years, epidemiologists have watched the same pattern: people with high blood pressure in midlife are more likely to develop dementia decades later. The correlation is robust, biologically plausible, and reproducible across cohorts. What nobody could show was causation. Trial after trial of blood pressure lowering, including the landmark American SPRINT-MIND study, pointed in the right direction but missed statistical significance, usually because they were too small, too short, or stopped early for cardiovascular benefit before the brain outcomes matured.
That has now changed. Researchers running the China Rural Hypertension Control Project randomized 326 villages, not individuals, to either usual care or an intensive program in which trained non-physician community health workers, supervised remotely by doctors, titrated medication using a fixed stepped protocol toward a target below 130 over 80. The design is the point. This was not a boutique intervention delivered by specialists in an academic center; it was cheap, protocol-driven care delivered by lay providers in villages, which is exactly how hypertension would have to be treated if the world wanted to act on the finding.
The pressure difference achieved was unusually large. Participants entered with a mean systolic pressure around 156 mmHg. After four years the treated group averaged 128 mmHg, the control group 148 mmHg, a gap of 22 mmHg. Roughly 68 percent of the intervention arm reached target versus 15 percent of controls.
Against that separation, dementia incidence fell from 1.31 percent per year to 1.12 percent per year, a 15 percent relative reduction that was statistically significant. Milder cognitive impairment fell in parallel. Earlier phases of the same trial had already reported a 33 percent drop in cardiovascular events and death, including 33 percent fewer strokes and 15 percent fewer deaths from any cause.
The big idea is that dementia, long treated as a neurodegenerative fate to be met with amyloid-directed drugs, is partly a vascular disease of the small arteries feeding the brain, and it is partly preventable with medicines that already cost pennies. There is no new molecule here. There is a delivery system, a target, and four years of follow-up showing that the brain responds to hemodynamics faster than most people assumed.
The caution is proportion. Fifteen percent relative is not fifteen percent absolute. Roughly 123 people needed treating for four years to prevent one case.
Actionable Insights
The practical message is narrow and strong: if your systolic blood pressure is above 140, treating it to below 130 appears to lower your dementia risk, not merely your stroke risk. This is the first randomized proof of that, and it comes from people whose average age was 63.
On magnitude, be honest about two different numbers. The relative reduction is 15 percent, which sounds substantial. The absolute reduction over four years is about 0.8 percentage points, which means roughly 123 people had to be treated for four years to prevent one dementia case. Expressed in the standardized units researchers use to compare interventions, the dementia effect corresponds to a Cohen’s d of about 0.08, which is conventionally called a very small effect. Milder cognitive impairment showed a larger absolute benefit, about 3.5 percentage points, or roughly 29 people treated to prevent one case.
The blood pressure change itself was large, a 22 mmHg systolic gap equal to a Cohen’s d near 1.1 to 1.2, so this is a big dose producing a small brain effect. Do not expect the same benefit from a 5 mmHg drop.
Two practical caveats. The benefit was clear below age 69 and not statistically significant above it, so starting earlier matters. And treated participants had fewer serious adverse events than controls, so the usual fear of overtreatment was not borne out here.
Context and Source
- Paywalled Paper: Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial
- Institutions Optimal Aging Institute and Departments of Medicine and Population Health, NYU Grossman School of Medicine, New York, USA; Aga Khan University, Karachi, Pakistan and Nairobi, Kenya; Stroke Branch, National Institute of Neurological Disorders and Stroke, Bethesda, USA.
- Primary trial: First Hospital of China Medical University, Shenyang, China, with collaborating institutions including UT Southwestern Medical Center, Tulane University and Wake Forest University School of Medicine, USA.
- Location: Trial conducted in rural China across three provinces.
- Journal: Nature Medicine.
- Impact: The impact score of this journal is 52.5 (2-year Journal Impact Factor, 2025, publisher-reported), evaluated against a typical high-end range of 0 to 60+ for top general science and medical journals, therefore this is an Elite impact journal.